Anti-FGFR2 / CD332 Reference Antibody (bemarituzumab)

• Catalog Number: orb1806350
• Category: Antibodies
• Description: Anti-FGFR2 / CD332 Reference Antibody is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.24 kDa.
• Clonality: Monoclonal
• Tested applications: ELISA, FA, FACS, Kinetics
• Reactivity: Human
• Isotype: IgG
• Purity: > 95%
• Conjugation: Unconjugated
• MW: 145.24 kDa
• Target: FGFR2 / CD332
• Endotoxins: < 1 EU/mg
• Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Buffer/Preservatives: 100 mM Pro-Ac 20 mM Arg pH 5.0
• Note: For research use only
• Expiration Date: 12 months from date of receipt.

Anti-FGFR2 / CD332 Reference Antibody (bemarituzumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

The purity of Anti-FGFR2 / CD332 Reference Antibody (bemarituzumab)is more than 100% ;determined by SEC-HPLC.

SNU-16 cells were stained with Anti-FGFR2 / CD332 Reference Antibody (bemarituzumab) and negative control protein respectively; washed and then followed by PE and analyzed with FACS; EC763=0.5368 μg/mL.

Anti-FGFR2 / CD332 Reference Antibody (bemarituzumab) induced ADCC activity was evaluated using Human FGFR2 HEK293 Reporter Cell.The max induction fold was approximately 25.

Anti-FGFR2 / CD332 Reference Antibody (bemarituzumab) -ADCC luciferase Assay on KATOIII cells. The maximum suppression factor is approximately 14.

Bemarituzumab inhibited the tumor growth of SNU-16 on Balb/c nude mice. The result showed significant anti-tumor effects; with an tumor inhibition rate (TGI) of 29.7% at 2 mpk at D62.